Cargando…

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

BACKGROUND: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic complet...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoellhammer, Hans F, Hsu, Felicia, Vito, Courtney, Chu, Peiguo, Park, Jinha, Waisman, James, Kim, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978138/
https://www.ncbi.nlm.nih.gov/pubmed/24708527
http://dx.doi.org/10.1186/1471-2407-14-242
_version_ 1782310519484448768
author Schoellhammer, Hans F
Hsu, Felicia
Vito, Courtney
Chu, Peiguo
Park, Jinha
Waisman, James
Kim, Joseph
author_facet Schoellhammer, Hans F
Hsu, Felicia
Vito, Courtney
Chu, Peiguo
Park, Jinha
Waisman, James
Kim, Joseph
author_sort Schoellhammer, Hans F
collection PubMed
description BACKGROUND: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic complete response in the primary breast cancer. However, little is known about its effects on metastatic liver disease. CASE PRESENTATION: We report the treatment of a 54-year-old female who was diagnosed with HER2-positive invasive ductal carcinoma and synchronous breast cancer liver metastasis (BCLM). The patient underwent eight cycles of standard docetaxel with two anti-HER2 targeted agents, trastuzumab and pertuzumab. Subsequent radiographic imaging demonstrated complete radiographic response in the primary lesion with an approximate 75% decrease in the liver metastasis. After informed consent the patient underwent modified radical mastectomy that revealed pathologic complete response. Re-staging demonstrated no new disease outside the liver and a left hepatectomy was performed for resection of BCLM. Final pathologic examination revealed no residual malignant cells in the liver specimen, indicating pathologic complete response. Herein, we discuss the anti-HER2 targeted agents trastuzumab and pertuzumab and review the data on dual HER2 antagonism for HER2-positive breast cancer and the role of surgical resection of BCLM. CONCLUSIONS: The role of targeted agents for metastatic HER2-positive breast cancer is under active clinical trial investigation and we await the maturation of trial results and long-term survival data. Our results suggest that these agents may also be effective for producing considerable pathologic response in patients with BCLM.
format Online
Article
Text
id pubmed-3978138
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39781382014-04-09 Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism Schoellhammer, Hans F Hsu, Felicia Vito, Courtney Chu, Peiguo Park, Jinha Waisman, James Kim, Joseph BMC Cancer Case Report BACKGROUND: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic complete response in the primary breast cancer. However, little is known about its effects on metastatic liver disease. CASE PRESENTATION: We report the treatment of a 54-year-old female who was diagnosed with HER2-positive invasive ductal carcinoma and synchronous breast cancer liver metastasis (BCLM). The patient underwent eight cycles of standard docetaxel with two anti-HER2 targeted agents, trastuzumab and pertuzumab. Subsequent radiographic imaging demonstrated complete radiographic response in the primary lesion with an approximate 75% decrease in the liver metastasis. After informed consent the patient underwent modified radical mastectomy that revealed pathologic complete response. Re-staging demonstrated no new disease outside the liver and a left hepatectomy was performed for resection of BCLM. Final pathologic examination revealed no residual malignant cells in the liver specimen, indicating pathologic complete response. Herein, we discuss the anti-HER2 targeted agents trastuzumab and pertuzumab and review the data on dual HER2 antagonism for HER2-positive breast cancer and the role of surgical resection of BCLM. CONCLUSIONS: The role of targeted agents for metastatic HER2-positive breast cancer is under active clinical trial investigation and we await the maturation of trial results and long-term survival data. Our results suggest that these agents may also be effective for producing considerable pathologic response in patients with BCLM. BioMed Central 2014-04-04 /pmc/articles/PMC3978138/ /pubmed/24708527 http://dx.doi.org/10.1186/1471-2407-14-242 Text en Copyright © 2014 Schoellhammer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Schoellhammer, Hans F
Hsu, Felicia
Vito, Courtney
Chu, Peiguo
Park, Jinha
Waisman, James
Kim, Joseph
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title_full Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title_fullStr Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title_full_unstemmed Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title_short Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
title_sort complete pathologic response of her2-positive breast cancer liver metastasis with dual anti-her2 antagonism
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978138/
https://www.ncbi.nlm.nih.gov/pubmed/24708527
http://dx.doi.org/10.1186/1471-2407-14-242
work_keys_str_mv AT schoellhammerhansf completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT hsufelicia completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT vitocourtney completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT chupeiguo completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT parkjinha completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT waismanjames completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism
AT kimjoseph completepathologicresponseofher2positivebreastcancerlivermetastasiswithdualantiher2antagonism